Status and phase
Conditions
Treatments
About
The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
66 participants in 1 patient group
Loading...
Central trial contact
Ke Liu, M.M
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal